<PAGE> 1
================================================================================
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-QSB
(Mark One)
[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934.
FOR THE QUARTERLY PERIOD ENDED MARCH 31, 1999
[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934.
FOR THE TRANSITION PERIOD FROM TO
------------------- ------------------
COMMISSION FILE NUMBER: 000-23-661
--------------------
ROCKWELL MEDICAL TECHNOLOGIES, INC.
(Exact name of small business issuer as specified in its charter)
MICHIGAN 38-3317208
------------------------------------ -----------------------------------
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
28025 OAKLAND OAKS DRIVE
WIXOM, MICHIGAN 48393
--------------------------------------
(Address of principal executive offices)
(248) - 449-3353
---------------------
Issuer's telephone number
(NONE)
-----------------------
(Former name, former address and former fiscal year, if changed since
last report)
Check whether the issuer: (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such
shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes [X] No
[ ]
State the number of shares outstanding of each of the issuer's classes of
common equity as of the latest practicable date: 4,830,450 Common Shares
outstanding and 3,625,000 Common Share Purchase Warrants outstanding as of April
28, 1999.
Transitional Small Business Disclosure Format (Check one):
Yes[ ] No [x]
================================================================================
<PAGE> 2
PART I - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS.
ROCKWELL MEDICAL TECHNOLOGIES, INC. AND SUBSIDIARY
CONSOLIDATED BALANCE SHEET
AS OF MARCH 31, 1999
(WHOLE DOLLARS)
(Unaudited)
<TABLE>
<CAPTION>
MARCH 31, 1999
--------------
ASSETS
<S> <C>
Cash and Cash Equivalents ...................................................... $ 1,273,510
Accounts Receivable, net of allowance for doubtful accounts of $55,745.......... 995,617
Inventory....................................................................... 254,817
Other Current Assets............................................................ 118,439
-----------
TOTAL CURRENT ASSETS......................................................... 2,642,383
Property and Equipment, net..................................................... 884,240
Other Noncurrent Assets......................................................... 138,396
Excess of Purchase Price over Fair Value of Net Assets Acquired, net............ 1,235,969
-----------
TOTAL ASSETS................................................................. $ 4,900,988
===========
LIABILITIES AND SHAREHOLDERS' EQUITY
Accounts Payable................................................................ $ 497,018
Accrued Liabilities............................................................. 167,639
-----------
TOTAL CURRENT LIABILITIES.................................................... 664,657
SHAREHOLDERS' EQUITY:
Common Shares, no par value, 4,830,450 shares issued and outstanding ........... 8,680,545
Common Share Purchase Warrants, 3,625,000 warrants issued and outstanding....... 251,150
Accumulated Deficit............................................................. (4,695,364)
-----------
4,236,331
-----------
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY................................... $ 4,900,988
===========
</TABLE>
The accompanying notes are an integral part of the consolidated financial
statements.
2
<PAGE> 3
ROCKWELL MEDICAL TECHNOLOGIES, INC. AND SUBSIDIARY
CONSOLIDATED INCOME STATEMENT
FOR THE THREE MONTHS ENDED MARCH 31, 1999 AND MARCH 31, 1998
(WHOLE DOLLARS)
(Unaudited)
<TABLE>
<CAPTION>
THREE MONTHS THREE MONTHS
ENDED ENDED
MARCH 31, 1999 MARCH 31, 1998
-------------- --------------
<S> <C> <C>
SALES .......................................................... $ 1,584,210 $ 973,160
Cost of Sales .................................................. 1,436,203 1,134,579
------------- -----------
GROSS MARGIN (DEFICIT) ........................................ 148,007 (161,419)
Selling, General and Administrative ............................ 530,891 389,273
------------- -----------
OPERATING LOSS................................................. (382,884) (550,692)
Interest Income, net ........................................... 24,747 11,107
------------- -----------
NET LOSS ...................................................... $ (358,137) $ (539,585)
============= ===========
Average shares outstanding........................................ 4,830,450 4,417,405
BASIC AND DILUTED LOSS PER SHARE ................................. $(.07) $(.12)
</TABLE>
The accompanying notes are an integral part of the consolidated financial
statements.
3
<PAGE> 4
ROCKWELL MEDICAL TECHNOLOGIES, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE THREE MONTHS ENDED MARCH 31, 1999 AND MARCH 31, 1998
(WHOLE DOLLARS)
(Unaudited)
<TABLE>
<CAPTION>
1999 1998
---- ----
<S> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss .................................................................... $ (358,137) $ (539,585)
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation and Amortization ............................................. 98,506 85,446
Compensation recognized for stock options ................................. 28,370 30,887
---------- ----------
(231,261) (423,252)
Changes in Working Capital:
Decrease (Increase) in Accounts Receivable .............................. (286,929) 8,849
Decrease (Increase) in Inventory ........................................ (32,722) 28,974
Increase in Other Assets ................................................ (53,422) (17,303)
Decrease in Accounts Payable ............................................ (31,690) (601,900)
Decrease in Other Liabilities ........................................... (5,709) (308,169)
---------- ----------
Net Change in Working Capital ......................................... (410,472) (889,549)
---------- ----------
NET CASH USED IN OPERATIONS ........................................ (641,733) (1,312,801)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of Equipment ....................................................... (17,954) (25,708)
---------- ----------
CASH USED IN INVESTING ACTIVITIES .................................. (17,954) (25,708)
CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance of Common Shares and Purchase Warrants ............................. -- 5,794,914
Cost of Initial Public Offering ............................................. -- 286,729
Repayment of notes payable .................................................. -- (200,000)
Redemption of Series A Preferred Stock ...................................... -- (1,095,915)
---------- ----------
CASH PROVIDED BY FINANCING ACTIVITIES .............................. -- 4,785,728
INCREASE (DECREASE) IN CASH .................................................. (659,687) 3,447,219
CASH AT BEGINNING OF PERIOD .................................................. 1,933,197 88,342
---------- ----------
CASH AT END OF PERIOD ........................................................ $1,273,510 $3,535,561
========== ==========
</TABLE>
Interest paid in 1998 upon the redemption of the Series A Preferred Stock was
$62,272.
The accompanying notes are an integral part of the consolidated
financial statements.
4
<PAGE> 5
ROCKWELL MEDICAL TECHNOLOGIES, INC. AND SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. ORGANIZATION AND CAPITALIZATION
Rockwell Medical Technologies, Inc. ("the Company") was incorporated on
October 25, 1996 for the purpose of purchasing and operating the business of
Rockwell Medical Supplies, L.L.C. and its sister company, Rockwell
Transportation, L.L.C. The Company is in the business of manufacturing and
distributing hemodialysis concentrates and dialysis kits to hemodialysis
clinics. The Company also packages, sells and distributes ancillary products
related to the hemodialysis process.
The Company is regulated by the Federal Food and Drug Administration under
the Federal Drug and Cosmetics Act, as well as by other federal, state and local
agencies. The Company currently has 510(k) approval from the FDA to market
hemodialysis solutions and powders.
On January 26, 1998 the Company issued 1,800,000 Common Shares and
3,105,000 Common Share Purchase Warrants pursuant to a Registration Statement
filed with the Securities and Exchange Commission. The offering price was $4.00
per share for the Common Shares and $.10 per warrant for the Common Share
Purchase Warrants. Net proceeds from this offering were approximately $5.8
million. Proceeds were used to redeem the Series A Preferred Shares, repay the
Notes Payable and reduce Accounts Payable and accrued expenses. The balance of
the funds was invested in short-term cash investments.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
BASIS OF PRESENTATION
The consolidated financial statements of the Company include the accounts
of Rockwell Medical Technologies, Inc. and its wholly owned subsidiary, Rockwell
Transportation, Inc. All intercompany balances and transactions have been
eliminated.
In the opinion of management, all necessary adjustments (consisting of
normal recurring adjustments) considered necessary for a fair presentation have
been included. The operating results for the three month period ended March 31,
1999 is not necessarily indicative of the results to be expected for the year
ending December 31, 1999.
A description of the Company's significant accounting policies can be
found in the footnotes to the Company's annual consolidated financial statements
for the year ended December 31, 1998 included in its Annual Report on Form
10-KSB dated March 30, 1999.
Certain reclassifications were made to the 1998 financial statements to
conform to the current year financial statement presentation.
5
<PAGE> 6
3. RELATED PARTY TRANSACTIONS
In July 1997, the Company obtained a demand loan from Karen Bagley in the
amount of $100,000 and in November 1997 the Company obtained a loan from Michael
J. Xirinachs in the amount of $100,000 due February 11, 1998. The loans bear
interest at an annual rate of 24%. These loans were repaid in January and
February 1998 with the proceeds of the Initial Public Offering. Karen Bagley is
the wife of Patrick Bagley, whose firm serves as legal counsel to the Company on
certain matters and also to Mr. Robert L. Chioini in a personal capacity.
Michael J. Xirinachs is a founder of the Company and was a Director of the
Company until January of 1999.
During each of the three month periods ended March 31, 1998 and 1999, the
Company paid fees to the consulting firm of Wall Street Partners, Inc. for
financial and management services. Amounts paid for the first quarter of 1998
were $75,000 and for the first quarter of 1999 were $60,000. During the first
quarter of 1998, the principals of the consulting firm were shareholders, and
members of the Board of Directors of the Company. Mr. Xirinachs withdrew from
the consulting firm and is no longer a consultant with Wall Street Partners,
Inc. nor is he currently a member of the Board of Directors of the Company.
ITEM 6. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED MARCH 31, 1999 AND 1998
Sales in the first quarter of 1999 were $1.6 million and were 63 % higher
than the first quarter of 1998. First quarter sales increased by $611,000 from
the year earlier period as a result of overall sales growth in the Company's
business. The Company's sales are primarily hemodialysis concentrates and
related ancillary products and supplies sold to hemodialysis providers. The
majority of the Company's revenues are from hemodialysis concentrates. The
Company realized sales growth of 67% in its hemodialysis concentrate products
as a result of a combination of increased volume, higher prices and the
introduction of new products from the year earlier period. Excluding new product
sales, concentrate sales increased by 50% compared to the first quarter last
year with average selling prices increasing by 12.8%.
Of the Company's 67% aggregate sales increase in its concentrate products,
new product sales accounted for 17% of the total concentrate sales increase for
the quarter over the year earlier period. The Company realized sales growth from
the introduction of Dry Sate(TM) Dry Acid Concentrate and Sterilytc(TM) Liquid
Bicarbonate. In addition to new product sales growth, the Company experienced
sales volume gains of 37% on its other concentrate products. Higher average
selling prices, ranging between 11% and 14%, were realized for concentrate
products. Overall, aggregate price increases generated in excess of $100,000 in
revenue in concentrate product sales compared to the first quarter of 1998.
The Company also derives revenue from the sale of ancillary products and
from back-haul revenue. For the quarter, ancillary sales were up 56% or $72,000
as compared to the first quarter of 1998. Approximately 50% of the increase was
from the sale of mixing equipment used by customers that use the Dri-Sate(TM)
Acid Concentrate product. Other ancillary sales increased about 30%. The Company
generates back-haul revenue from its truck fleet. In the first quarter,
back-haul revenue decreased by $3,000 compared to the year earlier period.
Gross profit margins for the quarter were 9.3% compared to a gross margin
deficit or 16.6% in the first quarter of 1998, for an improvement of 25.9 margin
points. The gross margin improvement was due to increased volume, higher average
selling prices, improved product mix, increased manufacturing efficiency and
reduced distribution costs as a percent of sales revenue. Overall, gross profit
dollars improved by $309,500 compared to the first quarter last year. Price
increases on concentrates contributed approximately one-third of the
improvement. Improved fleet utilization and reduced distribution costs also
benefited first quarter results compared to the first quarter last year.
Excluding the impact of price
6
<PAGE> 7
increases, overall concentrate product sales increased by 54% while overall
distribution costs increased by 27%. Similarly, manufacturing and labor
efficiencies were achieved with those costs up approximately 13% on a 54%
concentrate product volume increase.
Selling, General & Administrative expense for the quarter was $531,000
compared to $389,000 in the first quarter of 1998. First quarter 1999 costs to
sales were 33.5%, as a per cent of sales, which was 6.5 points lower than the
year earlier period of 40% to sales. Overall, Selling, General and
Administrative Expense increased by $142,000 or 36% compared to the first
quarter of 1998. The Company incurred additional costs as a result of becoming a
publicly traded company including expenses related to investor relations and
professional services which on a combined basis increased expenses by $55,000.
The Company has added sales resources which increased sales and marketing
expenses by $50,000. In addition, compensation expense was up $35,000 from the
year earlier period.
Interest Income for the first quarter of 1999 was $25,000 for the
quarter, which was $13,000 higher than the year earlier period.
The Company had a net loss of $358,137 for the quarter compared to a net
loss of $539,585 in the first quarter of 1998. Overall the net loss was reduced
by $181,448 which represented a 33% reduction in the loss level from the first
quarter of 1998. Basic and fully diluted earnings per share improved $0.05 to a
loss of ($0.07) as compared to a loss of ($0.12) per share in the first
quarter of 1998. Of the total $0.05 improvement in earnings per share, slightly
less than $0.01 of the improvement was due to an increase in the number of
Common Shares outstanding, which was due to the Company's Initial Public
Offering of its Common Shares in January of 1998.
LIQUIDITY AND CAPITAL RESOURCES
In 1998, the Company issued 1,800,000 Common Shares and 3,105,000 Common
Share Purchase Warrants in an Initial Public Offering on January 26, 1998. The
net offering proceeds of $5.8 million were used for: (a) payments for
redemption of the Series A Preferred Shares ($1.2 million), (b) payments of
accounts payable and certain liabilities ($1,100,000), and (c) repayment of
promissory notes ($217,000). The balance of the cash remaining, approximately
$3.3 million at that time, was intended to be used to fund operating cash needs,
capital equipment acquisitions and business development throughout the United
States.
At the end of the first quarter of 1999, the Company had cash balances and
short term investments of $1.3 million to fund its future operating cash needs.
The Company anticipates that it will continue to have a need for cash to
continue its business development efforts and to fund future operating losses.
The Company anticipates that it has sufficient cash resources to meet its
current cash requirements to fund operations over the next twelve months.
For the first quarter of 1999, the Company used $641,000 in cash to fund
operations, with $231,000 used to fund operating activities and a $410,000
increase in working capital. Working Capital increased during the quarter
largely due to an increase in accounts receivable of $287,000 in the quarter.
The Company anticipates that the current receivable level will be reduced during
the second quarter.
Capital spending for the quarter was $18,000 with the majority due to
information technology spending.
YEAR 2000 ISSUES AND CONSEQUENCES
The Company is continuing the process of reviewing its systems and those
of its key vendors and suppliers with respect to the impact of Year 2000. With
respect to its suppliers, the Company has initiated a review of its key
suppliers and has received assurance from its key suppliers that they have taken
steps to ensure that they will not interrupt the Company's supply chain and that
they have addressed or are addressing any Year 2000 impact on their respective
organizations. The Company believes that there are alternative sources of supply
for the primary materials used in its operations and therefore, has limited
exposure to a disruption in its supply chain.
7
<PAGE> 8
With respect to its internal information systems, the Company has
converted its financial and business operations systems to software that is Year
2000 compliant. Other non-information technology based systems and equipment do
not appear to have Year 2000 issues. The Company does not believe that the Year
2000 issues will have a material impact on the business.
8
<PAGE> 9
PART II - OTHER INFORMATION
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits
Exhibit No Description
---------- -----------
27.1 Financial Data Schedule
(b) Reports on Form 8-K
(None)
9
<PAGE> 10
SIGNATURES
In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by undersigned, thereunto duly
authorized.
ROCKWELL MEDICAL TECHNOLOGIES, INC.
(Registrant)
Date: May 7, 1999 /s/ ROBERT L. CHIOINI
--------------------------------
Robert L. Chioini
President, Chief Executive
Officer and Director (Principal
Executive Officer)
Date: May 7, 1999 /s/ THOMAS E. KLEMA
--------------------------------
Thomas E. Klema
Vice President of Finance, Chief
Financial Officer, Treasurer and
Secretary (Principal Financial
Officer and Principal Accounting
Officer)
10
<TABLE> <S> <C>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1999
<PERIOD-START> JAN-01-1999
<PERIOD-END> MAR-31-1999
<CASH> 1273510
<SECURITIES> 0
<RECEIVABLES> 1051362
<ALLOWANCES> 55745
<INVENTORY> 254817
<CURRENT-ASSETS> 2642383
<PP&E> 1312610
<DEPRECIATION> 428370
<TOTAL-ASSETS> 4900988
<CURRENT-LIABILITIES> 664657
<BONDS> 0
0
0
<COMMON> 8680545
<OTHER-SE> 251150
<TOTAL-LIABILITY-AND-EQUITY> 4900988
<SALES> 1584210
<TOTAL-REVENUES> 1584210
<CGS> 1436203
<TOTAL-COSTS> 1436203
<OTHER-EXPENSES> 530891
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> (358137)
<INCOME-TAX> 0
<INCOME-CONTINUING> (358137)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (358137)
<EPS-PRIMARY> (.07)
<EPS-DILUTED> (.07)
</TABLE>
